J.P. Morgan analyst Chris Schott maintained a Buy rating on Royalty Pharma (RPRX - Research Report) today and set a price target of $52.00. The...
NEW YORK, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2022...
NEW YORK, Oct. 17, 2022 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend...
Art McGivern joins Royalty Pharma as EVP, Investments & General CounselGeorge Lloyd promoted to EVP, Investments & Chief Legal Officer...
NEW YORK, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has entered into an agreement with Merck...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of...
NY false 0001802768 --12-31 0001802768 2022-09-30 2022-09-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C...
FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.